Bluejay Diagnostics, Inc.
BJDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 8.20 | -0.28 | -6.33 |
| FCF Yield | -909.91% | -13.48% | -2.33% | -0.17% |
| EV / EBITDA | 0.48 | -7.09 | -41.53 | -828.45 |
| Quality | ||||
| ROIC | -120.29% | -316.28% | -77.33% | -15.85% |
| Gross Margin | 0.00% | 0.00% | 19.64% | 0.00% |
| Cash Conversion Ratio | 1.01 | 0.84 | 0.83 | 1.25 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | – | – | – |
| Free Cash Flow Growth | 9.89% | -0.86% | -103.63% | -763.11% |
| Safety | ||||
| Net Debt / EBITDA | 0.61 | 0.20 | 1.07 | 6.18 |
| Interest Coverage | -8.71 | 0.00 | 0.00 | -8.79 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -266.05 | -229.70 | -1,159.62 | -740.87 |